Global law firm Goodwin today announced that a team of 14 partners has joined the firm in its Life Sciences, Healthcare, Private Equity and Complex Litigation and Dispute Resolution practices across a number of offices, including its newly-established Philadelphia office.
“Goodwin’s strategy is to be the firm of choice for clients doing business within the healthcare, life sciences, private equity, real estate, technology, and financial services sectors, and where they converge,” said Rob Insolia, Chair of Goodwin. “We produce results for our clients by combining our immersive understanding of these industries with our expertise across high-stakes litigation, investigations and dispute resolution, our world-class regulatory compliance and advisory services, and our unsurpassed ability to execute complex transactions. The team joining us aligns with our long-term strategy and will further scale Goodwin’s global capital-meets-innovation platform for the benefit of our clients.”
The team, which has most recently practiced together at a national US law firm, includes the following partners:
Healthcare Transactions and Regulatory
Government Enforcement, Investigations, and White Collar Defense
The Life Sciences; Healthcare Transactions and Regulatory; and Government Enforcement, Investigations, and White Collar Defense groups joining Goodwin are led by, respectively, Rachael Bushey, John Jones, and Thomas Gallagher.
“We are fortunate to continue to be at the forefront of representing companies, private equity investors, and banks operating within the dynamic and intertwined life sciences and healthcare industries, which have experienced exponential disruption, innovation, and acceleration over the past several years,” said, in a joint statement, Mitchell Bloom, Chair of Goodwin’s Life Sciences practice; Chris Wilson, Co-Chair of the firm’s Healthcare practice; and Kirk Ogrosky, Co-Lead of the firm’s Healthcare Government Enforcement & False Claims Act Defense practice. “Navigating this rapidly-evolving landscape requires a sophisticated understanding of – in equal measure – litigation, regulatory and advisory, and transactional trends impacting the life sciences and healthcare industries sectors and the players within them. In this respect, our global team is unparalleled. With the addition of the powerhouse group led by Rachael, John, and Tom, Goodwin will continue to be the most-informed and the most-connected choice for clients doing business in the life sciences and healthcare ecosystem.”
Bushey most recently chaired the Health Sciences department, and served on the Management and Policy committees, of her prior firm. She represents public and private life sciences companies in connection with a variety of capital markets transactions; Securities Exchange Act work; mergers and acquisitions; complex divestitures and carve-out transactions; and corporate governance. She has significant experience negotiating transactions with pharmaceutical and biotechnology companies.
Jones most recently chaired the Healthcare Transactions and Regulatory Practices of his prior firm. He focuses his practice in healthcare private equity and strategic M&A and complex federal and state health care regulatory matters. He represents financial sponsors and strategics on a wide range of corporate, M&A, regulatory, structure, governance and compliance matters. Clients with a stake in the health care industry rely on Jones to navigate their most important deals and complex issues.
Gallagher represents businesses and individuals facing federal and state government investigations and, qui tam litigation, particularly in life sciences and healthcare. Gallagher is a former Assistant U.S. Attorney from the criminal division of the US Attorney’s Office in the Eastern District of Pennsylvania. He brings significant experience handling False Claims Act, Foreign Corrupt Practices Act, and Antikickback Statute matters. Most of the partners join Goodwin in the new Philadelphia office. Goodwin established its Philadelphia presence in early 2022 when private equity partner Barb Shander joined the firm. With today’s announcement, Goodwin formally opens a Philadelphia office, which at the outset will include partners, and a group of associates who had joined with Shander.
Goodwin’s Life Sciences practice works with companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem. The Healthcare private equity and regulatory practice advises private equity firms and their portfolio companies, providers, digital health companies, women’s health and wellness companies, and investors on transactions, regulations, government investigations, and litigation. Goodwin has a long record of successfully defending clients in False Claims Act litigation and fraud and abuse investigations as well as on matters involving reimbursement disputes and disclosures to proactively mitigate risks. Most recently, Goodwin added partner Gregory Demske to the firm’s deep bench of former government regulators and federal prosecutors from key US Attorney’s offices and the DOJ.